Rchr
J-GLOBAL ID：201901012702492690
Update date: Oct. 19, 2023
Ommori Rie
オンモリ リエ | Ommori Rie
Research field (1)：
Dermatology
Research keywords (5)：
表皮ブドウ球菌
, 黄色ブドウ球菌
, 薬疹
, EGFR阻害薬
, 抗菌ペプチド
Research theme for competitive and other funds (4)：
- 2020 - 2023 分子標的治療薬による皮膚障害発症機序の解明
- 2018 - 2021 Study of skin innate immune response in cutaneous adverse effects caused by molecular targeted agents
- 2014 - 2015 分子標的治療薬が表皮自然免疫に及ぼす影響に着目した薬疹の病態解明
- 2013 - 2014 ブドウ球菌が表皮自然免疫応答に及ぼす影響に着目したアトピー性皮膚炎の病態解明
Papers (13)：
-
Yasuhiro Mitsui, Satoru Shinkuma, Yuki Nakamura-Nishimura, Rie Ommori, Kohei Ogawa, Fumi Miyagawa, Yasuko Mori, Mikiko Tohyama, Hideo Asada. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. The journal of allergy and clinical immunology. In practice. 2022. 10. 2. 558-565
-
R Ommori, Y Nakamura, F Miyagawa, C Shobatake, K Ogawa, F Koyama, M Sho, I Ota, T Kitahara, S Hontsu, et al. Reduced induction of human β-defensins is involved in the pathological mechanism of cutaneous adverse effects caused by epidermal growth factor receptor monoclonal antibodies. Clinical and experimental dermatology. 2020. 45. 8. 1055-1058
-
Kazuya Miyashita, Fumi Miyagawa, Yuki Nakamura, Rie Ommori, Hiroaki Azukizawa, Hideo Asada. Up-regulation of human herpesvirus 6B-derived microRNAs in the serum of patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Acta Dermato-Venereologica. 2018. 98. 6. 612-613
-
Nakamura-Nishimura Y, Miyagawa F, Miyashita K, Ommori R, Azukizawa H, Asada H. Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. British Journal of Dermatology. 2018. 178. 6. 1430-1432
-
Ommori R, Park K, Miyagawa F, Azukizawa H, Kanno M, Asada H. Epidermal growth factor receptor (EGFR) inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response. British Journal of Dermatology. 2018. 178. 3. 796-797
ｍore...
MISC (28)：
-
御守里絵. EGFR阻害薬による皮膚障害の発症機序. 日本皮膚免疫アレルギー学会雑誌. 2018. 2. 1. 77
-
正畠千夏, 御守里絵, 小豆澤宏明, 浅田秀夫. 薬疹・薬物障害 過酸化ベンゾイル外用にて改善したセツキシマブによるざ瘡様皮疹の3例. 皮膚科の臨床. 2018. 60. 1. 59-62-62
-
正畠 千夏, 御守 里絵, 小豆澤 宏明, 浅田 秀夫. Three Cases of Cetuximab-induced Acneiform Eruption Successfully Treated with Benzoyl Peroxide. 皮膚科の臨床. 2018. 60. 1. 59-62
-
K. Miyashita, F. Miyagawa, R. Ommori, Y. Nakamura, H. Azukizawa, H. Asada. HHV-6-derived microRNAs in the serum/PBMC of DIHS/DRESS patients. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2017. 137. 10. S268-S268
-
R. Ommori, K. Park, F. Miyagawa, H. Azukizawa, H. Asada. EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2017. 137. 5. S103-S103
ｍore...
Association Membership(s) (2)：
日本皮膚免疫アレルギー学会
, 日本研究皮膚科学会
